New York, NY -- (SBWIRE) -- 03/28/2018 -- Overview
Graves' ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves'ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740085-graves-ophthalmopathy-pipeline-review-h2-2017
The Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves' Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Graves' Ophthalmopathy - Overview
Graves' Ophthalmopathy - Therapeutics Development
Pipeline by Companies
Products under Development by Companies
Graves' Ophthalmopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves' Ophthalmopathy - Companies Involved in Therapeutics Development
Enceladus Pharmaceuticals BV
Graves' Ophthalmopathy - Drug Profiles
pasireotide ER - Drug Profile
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2740085-graves-ophthalmopathy-pipeline-review-h2-2017
About Wise Guy Reports
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.